• All mean scores showed a trend of improved health after 4 doses of KRN23 treatment. • Role limitations due to physical health was significantly improved after multiplicity correction. • Patient reported outcomes can provide valuable information in evaluating new treatments for XLH. status released display-pdf yes is-olf no is-manuscript no is-preprint no is-journal-matter no is-scanned no is-retracted no Received 2015 Dec 7; Revised 2016 Apr 15; Accepted 2016 May 11; Collection date 2016 Dec. 1.
← all excerpts
Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia.
1
—
—